NSG 6005 Pharm Weeks 1-3 Quiz (from
|\ |\ |\ |\ |\ |\ |\
operation FNP Class 11) QUESTIONS WITH |\ |\ |\ |\ |\ |\
ANSWERS
Genetic polymorphisms account for differences in metabolism,
|\ |\ |\ |\ |\ |\ |\
including:
1. Poor metabolizers, who lack a working enzyme
|\ |\ |\ |\ |\ |\ |\
2. Intermediate metabolizers, who have one working, wild-type
|\ |\ |\ |\ |\ |\ |\ |\
allele and one mutant allele
|\ |\ |\ |\
3. Extensive metabolizers, with two normally functioning alleles
|\ |\ |\ |\ |\ |\ |\
4. All of the above - CORRECT ANSWERS ✔✔4. All of the above
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
1. A need to monitor drugs metabolized by 2D6 for toxicity
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
2. Increased dosages needed of drugs metabolized by 2D6, such
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
as the selective serotonin reuptake inhibitors
|\ |\ |\ |\ |\
3. Decreased conversion of codeine to morphine by CYP 2D6
|\ |\ |\ |\ |\ |\ |\ |\ |\
,4. The need for lowered dosages of drugs, such as beta blockers -
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
CORRECT ANSWERS ✔✔2. Increased dosages needed of drugs
|\ |\ |\ |\ |\ |\ |\ |\ |\
metabolized by 2D6, such as the selective serotonin reuptake
|\ |\ |\ |\ |\ |\ |\ |\ |\
inhibitors
Rifampin is a nonspecific CYP450 inducer that may:
|\ |\ |\ |\ |\ |\ |\
1. Lead to toxic levels of rifampin and must be monitored closely
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
2. Cause toxic levels of drugs, such as oral contraceptives, when
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
coadministered
3. Induce the metabolism of drugs, such as oral contraceptives,
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
leading to therapeutic failure
|\ |\ |\
4. Cause nonspecific changes in drug metabolism - CORRECT
|\ |\ |\ |\ |\ |\ |\ |\ |\
ANSWERS ✔✔3. Induce the metabolism of drugs, such as oral
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
contraceptives, leading to therapeutic failure |\ |\ |\ |\
Inhibition of P-glycoprotein by a drug such as quinidine may lead
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
to:
1. Decreased therapeutic levels of quinidine
|\ |\ |\ |\ |\
2. Increased therapeutic levels of quinidine
|\ |\ |\ |\ |\
,3. Decreased levels of a coadministered drug, such as digoxin,
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
that requires P-
|\ |\
glycoprotein for absorption and elimination |\ |\ |\ |\
4. Increased levels of a coadministered drug, such as digoxin,
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
that requires P-
|\ |\
glycoprotein for absorption and elimination - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\
✔✔4. Increased levels of a coadministered drug, such as digoxin,
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
that requires P-
|\ |\ |\
glycoprotein for absorption and elimination |\ |\ |\ |\
Warfarin resistance may be seen in patients with VCORC1
|\ |\ |\ |\ |\ |\ |\ |\ |\
mutation, leading to: |\ |\
1. Toxic levels of warfarin building up
|\ |\ |\ |\ |\ |\
2. Decreased response to warfarin
|\ |\ |\ |\
3. Increased risk for significant drug interactions with warfarin
|\ |\ |\ |\ |\ |\ |\ |\
4. Less risk of drug interactions with warfarin - CORRECT
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
ANSWERS ✔✔2. Decreased response to warfarin
|\ |\ |\ |\ |\
Genetic testing for VCORC1 mutation to assess potential warfarin
|\ |\ |\ |\ |\ |\ |\ |\
resistance is required prior to prescribing warfarin.
|\ |\ |\ |\ |\ |\ |\
, 1. True
|\
2. False - CORRECT ANSWERS ✔✔2. False
|\ |\ |\ |\ |\ |\
Pharmacogenetic testing is required by the U.S. Food and Drug |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
Administration prior to prescribing: |\ |\ |\
1. Erythromycin
|\
2. Digoxin
|\
3. Cetuximab
|\
4. Rifampin - CORRECT ANSWERS ✔✔3. Cetuximab
|\ |\ |\ |\ |\ |\
Carbamazepine has a Black Box Warning recommending testing|\ |\ |\ |\ |\ |\ |\ |\
for the HLA-
|\ |\
B*1502 allele in patients with Asian ancestry prior to starting
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
therapy due to: |\ |\
1. Decreased effectiveness of carbamazepine in treating seizures
|\ |\ |\ |\ |\ |\ |\ |\
in Asian patients with the HLA-B*1502 allele
|\ |\ |\ |\ |\ |\
2. Increased risk for drug interactions in Asian patients with the
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
HLA-B*1502 allele |\
|\ |\ |\ |\ |\ |\ |\
operation FNP Class 11) QUESTIONS WITH |\ |\ |\ |\ |\ |\
ANSWERS
Genetic polymorphisms account for differences in metabolism,
|\ |\ |\ |\ |\ |\ |\
including:
1. Poor metabolizers, who lack a working enzyme
|\ |\ |\ |\ |\ |\ |\
2. Intermediate metabolizers, who have one working, wild-type
|\ |\ |\ |\ |\ |\ |\ |\
allele and one mutant allele
|\ |\ |\ |\
3. Extensive metabolizers, with two normally functioning alleles
|\ |\ |\ |\ |\ |\ |\
4. All of the above - CORRECT ANSWERS ✔✔4. All of the above
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
1. A need to monitor drugs metabolized by 2D6 for toxicity
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
2. Increased dosages needed of drugs metabolized by 2D6, such
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
as the selective serotonin reuptake inhibitors
|\ |\ |\ |\ |\
3. Decreased conversion of codeine to morphine by CYP 2D6
|\ |\ |\ |\ |\ |\ |\ |\ |\
,4. The need for lowered dosages of drugs, such as beta blockers -
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
CORRECT ANSWERS ✔✔2. Increased dosages needed of drugs
|\ |\ |\ |\ |\ |\ |\ |\ |\
metabolized by 2D6, such as the selective serotonin reuptake
|\ |\ |\ |\ |\ |\ |\ |\ |\
inhibitors
Rifampin is a nonspecific CYP450 inducer that may:
|\ |\ |\ |\ |\ |\ |\
1. Lead to toxic levels of rifampin and must be monitored closely
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
2. Cause toxic levels of drugs, such as oral contraceptives, when
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
coadministered
3. Induce the metabolism of drugs, such as oral contraceptives,
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
leading to therapeutic failure
|\ |\ |\
4. Cause nonspecific changes in drug metabolism - CORRECT
|\ |\ |\ |\ |\ |\ |\ |\ |\
ANSWERS ✔✔3. Induce the metabolism of drugs, such as oral
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
contraceptives, leading to therapeutic failure |\ |\ |\ |\
Inhibition of P-glycoprotein by a drug such as quinidine may lead
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
to:
1. Decreased therapeutic levels of quinidine
|\ |\ |\ |\ |\
2. Increased therapeutic levels of quinidine
|\ |\ |\ |\ |\
,3. Decreased levels of a coadministered drug, such as digoxin,
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
that requires P-
|\ |\
glycoprotein for absorption and elimination |\ |\ |\ |\
4. Increased levels of a coadministered drug, such as digoxin,
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
that requires P-
|\ |\
glycoprotein for absorption and elimination - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\
✔✔4. Increased levels of a coadministered drug, such as digoxin,
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
that requires P-
|\ |\ |\
glycoprotein for absorption and elimination |\ |\ |\ |\
Warfarin resistance may be seen in patients with VCORC1
|\ |\ |\ |\ |\ |\ |\ |\ |\
mutation, leading to: |\ |\
1. Toxic levels of warfarin building up
|\ |\ |\ |\ |\ |\
2. Decreased response to warfarin
|\ |\ |\ |\
3. Increased risk for significant drug interactions with warfarin
|\ |\ |\ |\ |\ |\ |\ |\
4. Less risk of drug interactions with warfarin - CORRECT
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
ANSWERS ✔✔2. Decreased response to warfarin
|\ |\ |\ |\ |\
Genetic testing for VCORC1 mutation to assess potential warfarin
|\ |\ |\ |\ |\ |\ |\ |\
resistance is required prior to prescribing warfarin.
|\ |\ |\ |\ |\ |\ |\
, 1. True
|\
2. False - CORRECT ANSWERS ✔✔2. False
|\ |\ |\ |\ |\ |\
Pharmacogenetic testing is required by the U.S. Food and Drug |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
Administration prior to prescribing: |\ |\ |\
1. Erythromycin
|\
2. Digoxin
|\
3. Cetuximab
|\
4. Rifampin - CORRECT ANSWERS ✔✔3. Cetuximab
|\ |\ |\ |\ |\ |\
Carbamazepine has a Black Box Warning recommending testing|\ |\ |\ |\ |\ |\ |\ |\
for the HLA-
|\ |\
B*1502 allele in patients with Asian ancestry prior to starting
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
therapy due to: |\ |\
1. Decreased effectiveness of carbamazepine in treating seizures
|\ |\ |\ |\ |\ |\ |\ |\
in Asian patients with the HLA-B*1502 allele
|\ |\ |\ |\ |\ |\
2. Increased risk for drug interactions in Asian patients with the
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
HLA-B*1502 allele |\
